Company Description
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally.
The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.
It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012.
Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. On February 13, 2024, Invitae Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.
| Country | United States |
| Founded | 2010 |
| IPO Date | Feb 12, 2015 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,700 |
Contact Details
Address: 1400 16th Street San Francisco, California 94103 United States | |
| Phone | (415) 374-7782 |
Stock Details
| Ticker Symbol | NVTAQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501134 |
| CUSIP Number | 46185L103 |
| ISIN Number | US46185L1035 |
| Employer ID | 27-1701898 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. Randal W. Scott Ph.D. | Co-Founder and Chairman of the Board |
| Kenneth D. Knight | President, Chief Executive Officer and Director |
| Thomas R. Brida | General Counsel, Chief Compliance Officer and Secretary |
| Ana J. Schrank | Chief Accounting Officer and Chief Financial Officer |
| Dr. David B. Sholehvar M.D. | Chief Operating Officer |
| Hoki Luk | Head of Investor Relations and Capital Markets and Corporate Development |
| Shelly D. Guyer | Chief Sustainability Officer |
| Desarie French | Chief Talent Officer |
| Dr. W. Michael Korn M.D. | Chief Medical Officer |
| Robert Guigley | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | 8-K | Current Report |
| Mar 6, 2024 | 8-K | Current Report |
| Feb 21, 2024 | 25-NSE | Filing |
| Feb 14, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | 8-K | Current Report |
| Feb 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |